www.thelancet.com/diabetes-endocrinology   Published online April 4, 2014   http://dx.doi.org/10.1016/S2213-8587(14)70029-4 1Articles Exenatide once weekly versus insulin glargine for type 2  diabetes (DURATION-3): 3-year results of an open-label randomised trial Michaela Diamant, Luc Van Gaal, Bruno Guerci, Stephen Stranks, Jenny Han, Jaret Malloy, Marilyn K Boardman, Michael E Trautmann Summary  Background When patients with type 2 diabetes start their ﬁ  rst injectable therapy , clinicians can choose between  glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3, exenatide once weekly was compared with insulin glargine (henceforth, glargine) as ﬁ  rst injectable therapy. Here, we report the results of the ﬁ  nal 3-year follow-up. Methods DURATION-3 was an open-label randomised trial done between May 13, 2008, and Jan 30, 2012. Patients